Dr. Maricich leads the Clinical/Regulatory team at Pear Therapeutics as the Chief Medical Officer and Head of Clinical Development. He leads and manages the clinical development programs from Discovery/TPP to Therapeutic, Translational, Clinical Development, through Regulatory submission and prosecution. In addition to overseeing subsequent pipeline programs, including reSET-O (1st drug/software combination), Dr. Maricich leads Medical Affairs. Dr. Maricich is a licensed, board-certified physician, investor, clinical developer and strategist. He works to improve patient health and our healthcare system by providing care, investing in, advising, and providing leadership at innovative firms. He has worked with and lead successful teams and programs at Healthcare & Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by Cavion), Cavion, AWS, and Pear Therapeutics (1st FDA-cleared, clinically validated digital therapeutic to treat disease) and maintains clinical practice. He founded a digital health firm while a 3rd year med student that used AI and NLP to structure clinical data. Dr. Maricich earned his M.D. degree at the University of Washington School of Medicine, M.B.A from Harvard University, and his undergraduate at the University of Notre Dame. He completed internal medicine training at the University of Virginia Health System.